Background and purpose -Orthopedics and especially joint replacement surgery have had more than their fair share of unsuccessful innovations that have violated widely endorsed principles for the introduction of new surgical innovations. We aimed to investigate (1) the trends in the use of the Birmingham Hip Resurfacing (BHR), the ASR hip resurfacing (ASR HRA) and the ASR XL total hip replacement (ASR XL THR) system with very different market approval processes and (2) whether their use was corroborated by clinical trials published in the peer-reviewed literature.
Methods -The literature was searched for any clinical studies that reported outcomes of the BHR, ASR HRA and ASR XL THRs. Data from 7 national hip arthroplasty registers were collected and the number of annually implanted devices was matched to those reported in the literature.
Results -The cumulative number of implanted and published BHRs grew proportionally with a small lag. The growth of implanted BHRs started to decline at the same time as the ASR HR was introduced. With regard to ASR HRAs, the cumulative proportion of implanted hips and those included in the published studies grew disproportionately after the introduction of the ASR in 2003. For ASR XL THRs, the disproportionality is even higher.
Interpretation -The adoption of ASR hip replacements did not follow the proposed stepwise introduction of orthopedic implants. The adoption and use of any new implant should follow a strict guideline and algorithm even if the theoretical basis or the results of preclinical studies are excellent.
■
The very foundation of current health care management is to have a robust, evidence-based approach. The IDEAL Collaboration (Idea, Development, Exploration, Assessment, Longterm follow-up) proposes that such an approach is characterized by: "the promotion of unbiased, highly reliable types of evidence" (Barkun et al. 2009) . A pragmatic approach taken by Haynes (1999) states that any innovation should work under ideal circumstances ("Can it work?") as well as the usual circumstances ("Does it work in practice?"). Unfortunately, orthopedics and especially the fi eld of joint replacement surgery have had more than their fair share of unsuccessful innovations that have violated these principles.
A detailed stepwise algorithm for the introduction of new orthopedic implants was established by Malchau (Malchau 2000 , Malchau et al. 2011 ). All new implants should go through a rigorous 4-step introduction process: preclinical step and clinical steps 1-3. The preclinical step includes preclinical testing, i.e., in hip simulators ("Can it work?"). Very similar guidelines related to the catastrophic failure of the 3M Capital Cemented Hip System in England in the 1990s were outlined by the Royal College of Surgeons of England (RCS) (2001) .
In the early 2000s, the Food and Drug Administration (FDA) in the United States exempted new devices from clinical trials if manufacturers could prove similarity to another product already on the market (Cohen 2012 , Day et al. 2016 ). In the European Union, a similar protocol was followed which granted approval (CE label) for any metal-on-metal (MoM) hip implant as long as the manufacturer was able to show similarity to a product already on the market (Cohen 2012) . Due to the similarity between the two approval procedures, in many cases the introduction of MoM implants in the United States and the European Union failed to meet any of the Clinical Step 1 processes outlined by Malchau et al. (2011) , namely, open prospective studies (usual circumstances, "Does it work?"). The Articular Surface Replacement (ASR) MoM hip resurfacing (HR) system and the ASR XL total hip replacement (THR) implant (Depuy Orthopaedics, Warsaw, IN), both of which led to catastrophic results, and many other hip resurfacing and large-diameter MoM THR designs were introduced claim-ing similarity to other MoM implants or their characteristics already on the market (U.S. FDA 2005 FDA , 2008 FDA 2006a FDA , 2006b .
Our main hypothesis is that the ASR hip replacement system was adopted into use far too rapidly and lacked the support of clinical results from published studies in the peer-reviewed literature. Hence, in this paper we aim to investigate (1) the trends in the use of the BHR and ASR hip replacements and (2) whether their use was corroborated by clinical trials published in the peer-reviewed literature.
Materials and methods
The MoM hip replacement brands investigated 3 different MoM hip arthroplasty brands were investigated: the BHR implant, the ASR HRA and the ASR XL THR implants.
Identifi cation of studies
We searched for clinical studies in the PubMed and Scopus databases. The search strategies and the PRISMA fl ow chart of the study selection are shown in Supplementary data, fi les 1-3.
Inclusion and exclusion criteria
A study was eligible if (1) it included an original patient cohort operated on with either the BHR, ASR HRA or ASR XL THR implants and, (2) the study clearly reported survival rate, revision rate or a failure rate. We defi ned an original patient cohort as a population of patients followed for a disclosed period and primarily operated on with a certain implant within a certain time interval at a disclosed hospital(s). If more than 1 implant was used and the number of patients for each implant was not given, the study was excluded. Furthermore, a study was excluded if (1) it included patients referred from somewhere other than the hospital(s) where the study was carried out (violation of eligibility criteria 1), or (2) more than 1 implant was used but the revisions were not stratifi ed by the implant.
If a study included a study arm or a subcohort of a study arm that had been included in a previous study with different follow-up periods, both studies were included since these were considered separate reports.
All the records retrieved from the 2 databases using our search strategy were screened. The screening of abstracts was done by two of the authors (AR and LL). All studies that outlined the use of any MoM hip implant or a hip implant under a brand name along with any clinical outcome (patient-reported outcome score, survival rate, failure rate, complication rate, revision rate, deaths, metal ion levels, cross-sectional imaging fi ndings) were selected for full-text review and eligibility assessment. Retrieval and eligibility assessment was done by the fi rst author (AR).
Data extraction
No detailed data extraction was carried out. The only data recorded were the number of hips included, the publication year and the type of implant used.
Registry data
Data were collected from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), the National Joint Registry for England and Wales (NJR), the Swedish Hip Arthroplasty Register (SHAR), the Finnish Arthroplasty Register (FAR), the New Zealand Joint Registry (NZJR), the Danish Hip Arthroplasty Register (DHR) and the Norwegian Arthroplasty Register (NAR). The annual reports available in the websites of respective registries were screened and the numbers of BHR, ASR hip resurfacings and ASR XL THR annually implanted were recorded. Data from the FAR were retrieved directly.
Full historical data on the use of the BHR were available from the AOANJRR, SHAR, FAR, NZJR, DHR and NAR. The annual report of the NJR was fi rst published in 2004. Therefore, data on the annual number of implanted BHRs in England and Wales between 1997 and 2002 were lacking. Full historical data on the use of the ASR hip replacements was available from all 7 registries.
Statistics
Data from published studies and registries were collected yearly ending in 2013. Since ASR hip replacements were recalled by the manufacturer in September 2010 and their use halted in 2011 at the latest, further data collection was not deemed feasible. The annual increase in both the implanted hips reported in the registries and the increase in the hips included in the published clinical studies were calculated. For each year, a running cumulative proportion of implanted and reported hips was calculated. This was achieved by dividing the cumulative number of implanted and reported hips in each year by the total cumulative number in the year 2013. Following this, the proportion of both implanted and reported hips was 1.0 in 2013 and smaller in the preceding years. The primary variable of interest was a time series consisting of cumulative number of implanted and reported hips as described above.
Results
89 studies were identifi ed. The details of all studies included are listed in Supplement 4. In the AOANJRR, NJR, FAR and DHR, the growth in implanted BHRs started to decline at the time the ASR HRA was fi rst introduced. Moreover, the use of the BHR peaked 1 to 2 years prior to the peak in use of the ASR HRA (Figure 1 ).
The trend in the use of the BHR was similar across AOAN-JRR, NJR, SHAR and FAR (Figure 2 ). In the 3 other registries variable patterns were seen. The proportion of other HR designs, especially the ASR HRA, increased rapidly from 2004. However, in 2010 the proportion of BHRs started to rise and the use of ASR came to an end due to the recall in September 2010.
In the studies that reported the results of the 3 implants, the number of hips included in the studies varied greatly from year to year (Supplementary data fi le 5). Figure 3 shows the relative proportion of reported and implanted hips annually. In 2013, both cumulative proportions reached 100% or a ratio of 1.0 (see Figure 3) . With the BHRs, a steady growth in the hips included in the published In the same year, the ASR hip system was recalled.
Discussion
An evidence-based approach to the introduction of surgical innovations is fundamental (Table 1) (Haynes 1999 , Malchau 2000 , McCulloch et al. 2009 ). This is especially true for joint replacement surgery since "the probability of success of modern innovations is very low due to the long-term success enjoyed by contemporary THA", as Malchau et al. (2011) stated, and as also stressed by the Balliol Collaboration behind the IDEAL guidelines (McCulloch et al. 2009 ). Unfortunately, the fi eld of joint replacement surgery has experienced very little success in achieving a rigorous stepwise introduction process (Nieuwenhuijse et al. 2014) . The "3M disaster" struck the UK in 1990 (Royal College of Surgeons of England 2001). The 3M Capital Hip was intended to be similar to the Charnley Hip with only slight modifi cations. These slight modifi cations had, however, a substantial adverse effect on the survival of the implant, and it was subsequently recalled. The current MoM disaster is the result of an identical series of catastrophic mistakes (Cohen 2011 (Cohen , 2012 . The open prospective studies required in Clinical Steps 1 and 2 of the stepwise introduction of implants suggested by Malchau (2000) and the clinical trials in the RCS 2001 recommendation are the responsibility of individual surgeons.
The FDA approved the BHR through premarket approval (PMA) (U.S. FDA 2006 FDA , 2009 . The ASR XL THR, on the other hand, gained the 510(k) clearance that relies on "proof of similarity" and is most often obtained by non-clinical tests. Moreover, the 510(k) application must state that devices are substantially equivalent. In 2005, the FDA approved the "ASR Acetabular Cup system", which introduced a MoM THR with femoral head sizes of 39 to 55 mm (U.S. FDA 2005). The predicate devices in the application, i.e., the devices with which similarity was claimed, were the Pinnacle MoM THR and the TRANSCEND MoM THR. Interestingly, the work by Ardaugh et al. (2013) shows that the ancestry of these 2 devices goes as far back as the McKee-Farrar hip and Ring hip prostheses. As late as 2008, the FDA cleared an extension to the "ASR Acetabular Cup System", namely the "ASR XL Acetabular System" that introduced femoral head sizes of 55 to 63 mm. The "ASR Acetabular Cup System" was named as a predicate device along with the TRANSCEND MoM THR and the "ASR 300 Acetabular Cup system", of which the latter had undergone no mechanical or clinical tests (U.S. FDA 2007, Ardaugh et al. 2013 ). The ASR HRA was not, however, approved by the FDA. Interestingly, the ASR femoral head designed for use in hemiarthroplasty surgery was approved using the previous poorly survived TARA implant as the equivalent device. Controversially, although the ASR HRA was not approved by the FDA, it was granted a CE marking in the European Union (Cohen 2011, House of Commons Science and Technology Committee 2012) .
Basically, a conceptual model of a healthy adoption of an innovation is a bell-shaped curve when the potential market share is depicted as described in "Diffusion of Innovations" by Rogers in 1962 and which was also co-adopted in surgical innovations by Wilson (2006) . The adoption of the ASR XL THA in some registers was clearly too fast, and in some registers the adoption phase can even be considered to be missing. This is most likely due to the marketing psychology, as largediameter MoM THRs were marketed as being identical to the BHR and other well-functioning HRs, and hence the adoption would not have been a problem. Moreover, large-diameter bearings with a stem were seen as ideal for reducing dislocation rate, and thus they were easily adopted for those patients unsuitable for hip resurfacing. Clearly, this was a disastrous phase as the hip simulator studies did not reveal the in vivo effects of increased modularity (taper-trunnion interface) and subsequent wear (Matthies et al. 2013) . The use of the BHR decreased quickly after the introduction of the ASR HRA. Moreover, there was a clear shift in the use of the hip resurfacing concept away from the BHR, with numerous studies available at the time, to other HR designs, mainly ASR. The adoption of the ASR hip resurfacing device was quite rapid. Again, this was most likely an industrydriven change since the similarity between the 2 was heavily emphasized, and because similarity was also a crucial step in the approval process. Yet again, this was a disastrous phase as the hip simulator studies did not reveal the in vivo effects of reduced clearance and especially the reduced cup hemisphericity on the wear of the bearing couple in the ASR hip (Underwood et al. 2012 , Matthies et al. 2014 .
The IDEAL guidelines state that after the fi rst stage ("Idea") comes stage 2a ("Development"). The collaboration behind the IDEAL guidelines demands that "prospective development studies" are performed in stage 2a (Table 1 ). This can be considered equal to the demand for open prospective studies proposed by Malchau (2000 Malchau ( , 2011 . Clearly, phase 2a in the IDEAL guidelines and the fi rst clinical step in the Malchau algorithm was too rapid or even lacking during the shift from the BHR to other HR designs, especially ASR HRA.
When data from the registries and from the literature are combined, obvious conclusions can be drawn. In an optimal situation, the number of studies and patients included would match how much the current innovation is used. The assumption is that as the adoption of an innovation spreads, the more people are likely to report the results of the innovations. However, after a certain level of adoption and spreading, a continuous fl ow of studies is not needed since the results will most likely be the same. With the BHR there was a suffi cient number of studies that included adequate numbers of patients Initial step = preclinical testing Stages 0-1 = Innovation Phase I = Preclinical trials "…the preclinical testing might increase both "pre-human work and development" "Full evaluation requires thorough pre-clinical the effi cacy and the safety of the innovation,…" "Single digit, highly selected patients" trials, e.g., by radio-stereometric analysis of "patient safety can often be improved stem migration,…" through iterative animal studies, use of simulators or augmented reality" Clinical step 1 = Prospective randomized studies Stage 2a = Development Phase II = Clinical trials "open prospective and preferably randomized "attempts to replicate reliably early "Ideally, randomized controlled trials should be trial that includes a minimum of patients but results should be made" carried out to evaluate the performance of yields a relevant evaluation" prostheses used for total hip replacement." "Results from this fi rst step determine whether further clinical evaluation is worthwhile" Stage 2b = Clinical step 2 = Multicenter studies Early dispersion and exploration "exposing the new procedure to a broader "enough reports have been published for aspect in the orthopaedic community" the technology to be generally regarded as safe and it is starting to lose its experimental character"
Stage 3 = Assessment "The procedure is now part of many surgeons' practices " "results have not been described in previously excluded groups"
Stage 4 = Long-term implementation Clinical step 3 = Register studies and monitoring Phase III = Post-marketing surveillance "to include a continuous control group by "surgeons to monitor late or rare "Three alternatives currently exist: using register studies based on large cohorts outcomes" (a) a registry; (b) post-market clinical trials; to reveal early or unusual and potential and (c) ad hoc analysis of adverse incidents clinical catastrophic complications" and user experience." "It is therefore recommended that a national hip registry should be established."
to provide evidence of its use following the years of introduction, at least in male patients. To sum up, in the case of BHR we postulate that there was causality between the registry and literature data meaning that the numbers reported in the registry predicted the numbers reported in the literature. For the ASR hip replacement, there is basically no evidence supporting its use. The use of ASR hip resurfacing peaked in 2007. Prior to 2007, only 1 study had been published (Siebel et al. 2006) . The disproportionality and lack of causality between the actual use and the evidence is even more catastrophic with the ASR XL THR. The concept was adopted extremely quickly violating the IDEAL guidelines and the Malchau algorithm as there was no evidence in the peer-reviewed literature to support their use. Both implants show a clear delay or a lag and the lack of a steady fl ow of studies in the peer-reviewed literature following the introduction of the implants.
Our study is not without limitations. The use of the ASR was also evident in North America. Since we are lacking openly available registry data from the USA and Canada, the global trends cannot be directly inferred from our data. Second, individual registries show some variation in the use of implants and hence the severity of the violation of the introduction process varies between countries.
To conclude, the introduction of the ASR hip replacement violated the fundamental principles of adoption by an almost complete lack of studies in the peer-reviewed literature following its introduction. The results obtained with hip simulators, the claims of similarity to or equivalence with other implants and theoretical advantages failed catastrophically to substitute for the most fundamental foundation of any innovation: the evidence in the literature. We should learn lessons from these recent mistakes made with hip replacements on a wider scale. The adoption and use of any new innovation should follow strict guidelines and algorithms even if the theoretical basis or the results of preclinical studies are excellent.
